Xeris Biopharma Holdings Inc.

News & Events

Press Releases

In The Media

1. Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

   Business Wire JUN 3, 2025 7:30 AM EDT
   Company to discuss long-range financial outlook and strategic roadmap for rapid and sustainable g...
   READ ARTICLE

2. Xeris Announces Details for Analyst & Investor Day

   Business Wire MAY 20, 2025 7:30 AM EDT
   Hybrid Event Offering In-Person or Virtual Attendance on Tuesday, June 3, 2025 Xeris ...
   READ ARTICLE

3. Xeris Biopharma Reports Record First Quarter 2025 Financial Results 

   Business Wire MAY 8, 2025 7:00 AM EDT
   Total revenue increased 48% YoY to over $60 million Recorlev ® revenue grew 141%...
   READ ARTICLE

4. Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

   Business Wire MAY 1, 2025 7:00 AM EDT
   Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company commit...
   READ ARTICLE

5. Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

   GlobeNewswire APR 17, 2025 7:00 AM EDT
   SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a...
   READ ARTICLE

6. Xeris Announces Changes to Its Board of Directors

   Business Wire MAR 28, 2025 8:00 AM EDT
   Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company commit...
   READ ARTICLE

7. Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx(TM) (glucagon) for Use as a Diagnostic Aid

   Business Wire MAR 17, 2025 8:00 AM EDT
   First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroentero...
   READ ARTICLE

8. Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

   Business Wire MAR 6, 2025 7:00 AM EST
   Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% vers...
   READ ARTICLE

9. Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

   Business Wire FEB 27, 2025 7:00 AM EST
   Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS...
   READ ARTICLE

10. Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

    Business Wire FEB 24, 2025 8:00 AM EST
    Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xer...
    READ ARTICLE